Last reviewed · How we verify
Long-term Dosing Cohort — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Long-term Dosing Cohort (Long-term Dosing Cohort) — Shaanxi Micot Pharmaceutical Technology Co., Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Long-term Dosing Cohort TARGET | Long-term Dosing Cohort | Shaanxi Micot Pharmaceutical Technology Co., Ltd. | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Long-term Dosing Cohort CI watch — RSS
- Long-term Dosing Cohort CI watch — Atom
- Long-term Dosing Cohort CI watch — JSON
- Long-term Dosing Cohort alone — RSS
Cite this brief
Drug Landscape (2026). Long-term Dosing Cohort — Competitive Intelligence Brief. https://druglandscape.com/ci/long-term-dosing-cohort. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing